RNA – avidity biosciences, inc. (US:NASDAQ)
Stock Stats
News
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Announces Expected Record Date for Spin-Off [Yahoo! Finance]
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences (NASDAQ:RNA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form DEFA14A Avidity Biosciences,
Form 10-K Avidity Biosciences, For: Dec 31
Form 8-K Avidity Biosciences, For: Feb 23
Form DEFA14A Avidity Biosciences,
Form SCHEDULE 13G/A Avidity Biosciences, Filed by: JANUS HENDERSON GROUP PLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.